Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications
- PMID: 26344890
- PMCID: PMC4494248
- DOI: 10.3390/vaccines2040755
Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications
Abstract
The LC16m8 strain of vaccinia virus, the active ingredient in the Japanese smallpox vaccine, was derived from the Lister/Elstree strain. LC16m8 is replication-competent and has been administered to over 100,000 infants and 3,000 adults with no serious adverse reactions. Despite this outstanding safety profile, the occurrence of spontaneously-generated large plaque-forming virulent LC16m8 revertants following passage in cell culture is a major drawback. We identified the gene responsible for the reversion and deleted the gene (B5R) from LC16m8 to derive LC16m8Δ. LC16m8∆ is non-pathogenic in immunodeficient severe combined immunodeficiency (SCID) mice, genetically-stable and does not reverse to a large-plaque phenotype upon passage in cell culture, even under conditions in which most LC16m8 populations are replaced by revertants. Moreover, LC16m8∆ is >500-fold more effective than the non-replicating vaccinia virus (VV), Modified Vaccinia Ankara (MVA), at inducing murine immune responses against pathogenic VV. LC16m8∆, which expresses the SIV gag gene, also induced anti-Gag CD8⁺ T-cells more efficiently than MVA and another non-replicating VV, Dairen I minute-pock variants (DIs). Moreover, LC16m8∆ expressing HIV-1 Env in combination with a Sendai virus vector induced the production of anti-Env antibodies and CD8⁺ T-cells. Thus, the safety and efficacy of LC16m8∆ mean that it represents an outstanding platform for the development of human vaccine vectors.
Keywords: B5R; DIs; HIV; LC16m8; LC16m8∆; MVA; SIV; reversion; vaccinia virus.
Figures



Similar articles
-
Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain.Biology (Basel). 2021 Nov 9;10(11):1158. doi: 10.3390/biology10111158. Biology (Basel). 2021. PMID: 34827150 Free PMC article. Review.
-
Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1. Vaccine. 2015. PMID: 26241947
-
Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. doi: 10.1073/pnas.0406671102. Epub 2005 Mar 7. Proc Natl Acad Sci U S A. 2005. PMID: 15753319 Free PMC article.
-
Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate.Microbiol Immunol. 2006;50(12):989-1000. doi: 10.1111/j.1348-0421.2006.tb03867.x. Microbiol Immunol. 2006. PMID: 17179668
-
Vaccines against mpox: MVA-BN and LC16m8.Expert Rev Vaccines. 2024 Jan-Dec;23(1):796-811. doi: 10.1080/14760584.2024.2397006. Epub 2024 Sep 1. Expert Rev Vaccines. 2024. PMID: 39188013 Review.
Cited by
-
CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.J Virol. 2021 Jan 28;95(4):e01718-20. doi: 10.1128/JVI.01718-20. Print 2021 Jan 28. J Virol. 2021. PMID: 33087465 Free PMC article.
-
Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain.Biology (Basel). 2021 Nov 9;10(11):1158. doi: 10.3390/biology10111158. Biology (Basel). 2021. PMID: 34827150 Free PMC article. Review.
-
Treatment and Vaccination for Smallpox and Monkeypox.Adv Exp Med Biol. 2024;1451:301-316. doi: 10.1007/978-3-031-57165-7_19. Adv Exp Med Biol. 2024. PMID: 38801586 Review.
-
Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study.Front Immunol. 2022 Sep 29;13:1005476. doi: 10.3389/fimmu.2022.1005476. eCollection 2022. Front Immunol. 2022. PMID: 36248835 Free PMC article.
-
Malaria bivalent viral vectored vaccine protects against Plasmodium falciparum and vivax and blocks parasite transmission.NPJ Vaccines. 2025 Jul 26;10(1):171. doi: 10.1038/s41541-025-01229-3. NPJ Vaccines. 2025. PMID: 40715105 Free PMC article.
References
-
- Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D., Organization W.H. Smallpox and Its Eradication. World Health Organization; Geneva, Switzerland: 1988.
-
- Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., Hauer J., Layton M., McDade J., Osterholm M.T., et al. Smallpox as a biological weapon: Medical and public health management. Working group on civilian biodefense. JAMA. 1999;281:2127–2137. doi: 10.1001/jama.281.22.2127. - DOI - PubMed
-
- The Centers for Disease Control and Prevention Multistate outbreak of monkeypox—Illinois, indiana, and wisconsin, 2003. JAMA. 2003;290:30–31. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials